A platform for glycoengineering a polyvalent pneumococcal bioconjugate vaccine using E. coli as a host

Bioconjugation is a promising process to manufacture conjugate vaccines, but currently employed enzymes cannot generate the full spectrum of bacterial glycoproteins. Here, the authors use an O-linking oligosaccharyltransferase to generate a polyvalent pneumococcal bioconjugate vaccine with polysacch...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Christian M. Harding, Mohamed A. Nasr, Nichollas E. Scott, Guillaume Goyette-Desjardins, Harald Nothaft, Anne E. Mayer, Sthefany M. Chavez, Jeremy P. Huynh, Rachel L. Kinsella, Christine M. Szymanski, Christina L. Stallings, Mariela Segura, Mario F. Feldman
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2019
Materias:
Q
Acceso en línea:https://doaj.org/article/def4f3d9176a44dbb8129ca597b1866c
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Bioconjugation is a promising process to manufacture conjugate vaccines, but currently employed enzymes cannot generate the full spectrum of bacterial glycoproteins. Here, the authors use an O-linking oligosaccharyltransferase to generate a polyvalent pneumococcal bioconjugate vaccine with polysaccharides containing glucose at their reducing end.